Accueil > Support > Références

Références

Receptor-Interacting Protein 3/Calmodulin-Dependent Kinase II/Proline-Rich Tyrosine Kinase 2 Pathway is Involved in Programmed Cell Death in a Mouse Model of Brain Ischaemic Stroke

Wang B, Ma L, Liu L, et al. Receptor-Interacting Protein 3/Calmodulin-Dependent Kinase II/Proline-Rich Tyrosine Kinase 2 Pathway is Involved in Programmed Cell Death in a Mouse Model of Brain Ischaemic Stroke. Neuroscience. 2022;506:14-28. doi:10.1016/j.neuroscience.2022.09.009

Produits recommandés : GAPDH acheté chez abinScience 2022-12-01
Design and Structural Optimization of Orally Bioavailable SOS1 Inhibitors for the Treatment of KRAS-Driven Carcinoma

He, H., Zhang, Y., Xu, J., Liu, Y., Wang, Z., Li, Y.,... & Zhang, S. (2022). Design and Structural Optimization of Orally Bioavailable SOS1 Inhibitors for the Treatment of KRAS-Driven Carcinoma. Journal of Medicinal Chemistry, 65(23), 16001-16016.

Produits recommandés : Recombinant Human KRAS/K-Ras 2 (G12C) Protein acheté chez abinScience 2022-11-17
Design and Structural Optimization of Orally Bioavailable SOS1 Inhibitors for the Treatment of KRAS-Driven Carcinoma

He, H., Zhang, Y., Xu, J., Liu, Y., Wang, Z., Li, Y.,... & Zhang, S. (2022). Design and Structural Optimization of Orally Bioavailable SOS1 Inhibitors for the Treatment of KRAS-Driven Carcinoma. Journal of Medicinal Chemistry, 65(23), 16001-16016.

Produits recommandés : Recombinant Human KRAS/K-Ras 2 (G12C) Protein acheté chez abinScience 2022-11-17
Molecular mimicry of the receptor-binding domain of the SARS-CoV-2 spike protein: from the interaction of spike-specific antibodies with transferrin and lactoferrin to the antiviral effects of human recombinant lactoferrin

Sokolov, A. V., Isakova‑Sivak, I. N., Mezhenskaya, D. A., Kostevich, V. A., Gorbunov, N. P., Elizarova, A. Yu., Matyushenko, V. A., Berson, Yu. M., Grudinina, N. A., Kolmakov, N. N., Zabrodskaya, Y. A., Komlev, A. S., Semak, I. V., Budevich, A. I., Rudenko, L. G., Vasilyev, V. B. (2022). Molecular mimicry of the receptor-binding domain of the SARS‑CoV‑2 spike protein: from the interaction of spike‑specific antibodies with transferrin and lactoferrin to the antiviral effects of human recombinant lactoferrin. Biometals, 36(3), 437–462.

Produits recommandés : Recombinant SARS-CoV-2 S - Trimer acheté chez abinScience 2022-11-05
Molecular mimicry of the receptor-binding domain of the SARS-CoV-2 spike protein: from the interaction of spike-specific antibodies with transferrin and lactoferrin to the antiviral effects of human recombinant lactoferrin

Sokolov, A. V., Isakova‑Sivak, I. N., Mezhenskaya, D. A., Kostevich, V. A., Gorbunov, N. P., Elizarova, A. Yu., Matyushenko, V. A., Berson, Yu. M., Grudinina, N. A., Kolmakov, N. N., Zabrodskaya, Y. A., Komlev, A. S., Semak, I. V., Budevich, A. I., Rudenko, L. G., Vasilyev, V. B. (2022). Molecular mimicry of the receptor-binding domain of the SARS‑CoV‑2 spike protein: from the interaction of spike‑specific antibodies with transferrin and lactoferrin to the antiviral effects of human recombinant lactoferrin. Biometals, 36(3), 437–462.

Produits recommandés : Recombinant SARS-CoV-2 S - Trimer acheté chez abinScience 2022-11-05
SARS-CoV-2 evolves to reduce but not abolish neutralizing action

Zhang Y, Ndzouboukou JB, Lin X, et al. SARS-CoV-2 evolves to reduce but not abolish neutralizing action. J Med Virol. 2023;95(1):e28207. doi:10.1002/jmv.28207

Produits recommandés : Research Grade Bamlanivimab Research Grade Casirivimab Research Grade lmdevimab Research Grade Etesevimab acheté chez abinScience 2022-10-19
SARS-CoV-2 evolves to reduce but not abolish neutralizing action

Zhang Y, Ndzouboukou JB, Lin X, et al. SARS-CoV-2 evolves to reduce but not abolish neutralizing action. J Med Virol. 2023;95(1):e28207. doi:10.1002/jmv.28207

Produits recommandés : Research Grade Bamlanivimab Research Grade Casirivimab Research Grade lmdevimab Research Grade Etesevimab acheté chez abinScience 2022-10-19
Discovery of Orally Bioavailable SOS1 Inhibitors for Suppressing KRAS-Driven Carcinoma

He, H., Zhang, Y., Xu, J., Li, Y., Fang, H., Liu, Y., Zhang, S., … (2022). Discovery of orally bioavailable SOS1 inhibitors for suppressing KRAS‑driven carcinoma. Journal of Medicinal Chemistry, 65(19), 13158–13171.

Produits recommandés : Recombinant Human KRAS/K-Ras 2 (G12C) Protein N-GST acheté chez abinScience 2022-09-29
Discovery of Orally Bioavailable SOS1 Inhibitors for Suppressing KRAS-Driven Carcinoma

He, H., Zhang, Y., Xu, J., Li, Y., Fang, H., Liu, Y., Zhang, S., … (2022). Discovery of orally bioavailable SOS1 inhibitors for suppressing KRAS‑driven carcinoma. Journal of Medicinal Chemistry, 65(19), 13158–13171.

Produits recommandés : Recombinant Human KRAS/K-Ras 2 (G12C) Protein N-GST acheté chez abinScience 2022-09-29
M6 A Modifier-Mediated Methylation Characterized by Diverse Prognosis, Tumor Microenvironment, and Immunother

Liu, F., et al. (2022). M6A modifier‑mediated methylation characterized by diverse prognosis, tumor microenvironment, and immunotherapy response in hepatocellular carcinoma. [Journal unspecified].

Produits recommandés : GAPDH acheté chez abinScience 2022-08-16

Obtenir un devis gratuit